Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project

NCT05933876 is registered in ClinicalTrials.gov with Institut Investigacio Sanitaria Pere Virgili as lead sponsor.

NCT NCT05933876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05933876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project
Lead sponsor
Institut Investigacio Sanitaria Pere Virgili
Phase
Observational
Overall status
Recruiting
Start date
December 1, 2022
Completion date
December 31, 2037
Enrollment
2,000 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis, metastatic breast cancer, metastatic colorectal cancer, metastatic lung cancer, metastatic prostate cancer